Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Trial Profile

A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Reloxaliase (Primary)
  • Indications Hyperoxaluria; Primary hyperoxaluria
  • Focus Therapeutic Use
  • Sponsors Allena Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to an Allena Pharmaceuticals media release, interim data from the trial is expected in the first half of 2019 and top-line data is expected in the second half of 2019.
    • 23 Jul 2018 According to an Allena Pharmaceuticals media release, patient enrolment is expected to begin at European sites in the third quarter of 2018.
    • 23 Jul 2018 According to an Allena Pharmaceuticals media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top